ATE540681T1 - Verfahren zur behandlung von atherosklerose - Google Patents
Verfahren zur behandlung von atheroskleroseInfo
- Publication number
- ATE540681T1 ATE540681T1 AT07796488T AT07796488T ATE540681T1 AT E540681 T1 ATE540681 T1 AT E540681T1 AT 07796488 T AT07796488 T AT 07796488T AT 07796488 T AT07796488 T AT 07796488T AT E540681 T1 ATE540681 T1 AT E540681T1
- Authority
- AT
- Austria
- Prior art keywords
- treating atherosclerosis
- thrombosis
- cholesterol
- inflammation
- accumulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81641506P | 2006-06-26 | 2006-06-26 | |
PCT/US2007/014873 WO2008002591A2 (en) | 2006-06-26 | 2007-06-26 | Methods for treating atherosclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE540681T1 true ATE540681T1 (de) | 2012-01-15 |
Family
ID=38786909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07796488T ATE540681T1 (de) | 2006-06-26 | 2007-06-26 | Verfahren zur behandlung von atherosklerose |
Country Status (7)
Country | Link |
---|---|
US (3) | US20080096900A1 (de) |
EP (2) | EP2452683A3 (de) |
AT (1) | ATE540681T1 (de) |
AU (1) | AU2007265475B2 (de) |
CA (2) | CA2787343C (de) |
ES (1) | ES2376396T3 (de) |
WO (1) | WO2008002591A2 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
EA201070187A1 (ru) * | 2007-07-26 | 2010-08-30 | Эмджен Инк. | Модифицированные ферменты лецитин-холестерин ацилтрансферазы |
US20110150976A1 (en) * | 2008-09-10 | 2011-06-23 | Transpharma Medical Ltd. | Transdermal delivery of oligosaccharides |
BRPI1012910A2 (pt) * | 2009-06-12 | 2020-06-02 | Alphacore Pharma Llc | Uso de um agente que leva a atividade de lcat ou eleva o nível de plasma do lcat ou ambos e composição farmacêutica compreendendo tal agente |
WO2011081667A1 (en) * | 2009-12-31 | 2011-07-07 | Immunitor USA, Inc. | Composition for atherosclerosis, obesity and obesity-related disorders |
DK2566505T3 (da) | 2010-05-06 | 2020-01-20 | Alphacore Pharma Llc | Fremføring af kolesterylester til steroidogene væv |
PE20130751A1 (es) * | 2010-08-16 | 2013-06-21 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrieno |
EP2609092B1 (de) | 2010-08-26 | 2015-04-01 | Boehringer Ingelheim International GmbH | Oxadiazolhemmer der leukotrienproduktion |
AU2011305667A1 (en) | 2010-09-23 | 2013-03-21 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
JP5828188B2 (ja) | 2010-09-23 | 2015-12-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン産生のオキサジアゾール阻害剤 |
CN104220460A (zh) | 2011-12-08 | 2014-12-17 | 安姆根有限公司 | 激动人lcat抗原结合蛋白和它们在疗法中的用途 |
AR089853A1 (es) | 2012-02-01 | 2014-09-24 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso |
CA2876382A1 (en) | 2012-06-14 | 2013-12-19 | Daiichi Sankyo Company, Limited | Piperidinylpyrazolopyridine derivative |
WO2015050148A1 (ja) * | 2013-10-04 | 2015-04-09 | 第一三共株式会社 | 3-アリールピラゾロピリジン誘導体 |
US9796709B2 (en) * | 2013-12-13 | 2017-10-24 | Daiichi Sankyo Company, Limited | 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative |
WO2015087996A1 (ja) * | 2013-12-13 | 2015-06-18 | 第一三共株式会社 | イミダゾピリジン誘導体 |
WO2015111545A1 (ja) * | 2014-01-21 | 2015-07-30 | 第一三共株式会社 | 縮合ピラゾール誘導体 |
TWI713534B (zh) | 2015-06-11 | 2020-12-21 | 日商第一三共股份有限公司 | 5-羥基-4-(三氟甲基)吡唑并吡啶衍生物之結晶及其用途 |
EP3490579A1 (de) | 2016-07-27 | 2019-06-05 | Hartis-Pharma SA | Therapeutische kombinationen zur behandlung von erythrozytendysfunktionen |
WO2019100086A2 (en) * | 2017-11-15 | 2019-05-23 | Parodi Juan C | System for optimal hydration |
JPWO2019189046A1 (ja) * | 2018-03-30 | 2021-04-08 | 第一三共株式会社 | Lcat欠損症治療薬 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
JPS63167409A (ja) | 1986-12-27 | 1988-07-11 | Yamaha Corp | 磁気記録体 |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
NL8720442A (nl) | 1986-08-18 | 1989-04-03 | Clinical Technologies Ass | Afgeefsystemen voor farmacologische agentia. |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
US6288095B1 (en) | 1987-09-04 | 2001-09-11 | Beecham Group P.L.C. | Compounds |
EP0842925A1 (de) | 1987-09-04 | 1998-05-20 | Beecham Group Plc | Substituierte Thiazolidindionderivate |
DE3889853D1 (de) | 1987-11-05 | 1994-07-07 | Hybritech Inc | Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik. |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
NZ241954A (en) | 1991-03-15 | 1994-01-26 | Amgen Inc | Compositions of g-csf for pulmonary administration. |
HU217629B (hu) | 1991-12-12 | 2000-03-28 | Novartis Ag. | Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására |
ATE156158T1 (de) | 1992-04-14 | 1997-08-15 | Cornell Res Foundation Inc | Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung |
US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
US5741803A (en) | 1992-09-05 | 1998-04-21 | Smithkline Beecham Plc | Substituted thiazolidinedionle derivatives |
WO1994016693A1 (en) | 1993-01-19 | 1994-08-04 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
FR2731710B1 (fr) | 1995-03-14 | 1997-04-30 | Rhone Poulenc Rorer Sa | Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
DE69616808T2 (de) | 1995-07-17 | 2002-05-29 | Warner Lambert Co | Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin) |
EP0871713B1 (de) * | 1995-11-09 | 2007-02-14 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atherosklerose |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
FR2758459B1 (fr) | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
DE69836626T2 (de) * | 1997-04-11 | 2007-04-05 | Takeda Pharmaceutical Co. Ltd. | Proteine mit lecithin-cholesterin acetyltransferase-ähnlicher aktivität, deren herstellung und verwendung |
US6692909B1 (en) * | 1998-04-01 | 2004-02-17 | Whitehead Institute For Biomedical Research | Coding sequence polymorphisms in vascular pathology genes |
DK0974356T3 (da) | 1998-07-15 | 2003-10-27 | Merck Sante Sas | Tabletter omfattende en kombination af metformin og glibenclamid |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
EP1263458B1 (de) | 2000-03-08 | 2005-11-16 | Novo Nordisk A/S | Senkung des serum cholesterols |
US6596544B1 (en) * | 2000-03-31 | 2003-07-22 | The Regents Of The University Of California | Functional assay of high-density lipoprotein |
WO2003096983A2 (en) * | 2002-05-17 | 2003-11-27 | Esperion Therapeutics, Inc. | Method of treating dyslipidemic disorders |
US20050101565A1 (en) * | 2002-07-03 | 2005-05-12 | Esperion Therapeutics, Inc. | Pharmaceutical compositions and methods for treating, preventing, and managing cholesterol, dyslipidemia, and related disorders |
WO2004022004A2 (en) | 2002-09-06 | 2004-03-18 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
MXJL05000046A (es) | 2003-04-22 | 2005-12-22 | Avanir Pharmaceuticals | Mediadores de transporte reverso de colesterol para el tratamiento de hipercolesterolemia. |
WO2004103310A2 (en) * | 2003-05-20 | 2004-12-02 | New England Medical Center Hospitals, Inc. | Methods and compositions for the treatment of metabolic disorders |
-
2007
- 2007-06-26 EP EP11008409A patent/EP2452683A3/de not_active Withdrawn
- 2007-06-26 AT AT07796488T patent/ATE540681T1/de active
- 2007-06-26 EP EP07796488A patent/EP2037928B1/de active Active
- 2007-06-26 CA CA2787343A patent/CA2787343C/en active Active
- 2007-06-26 AU AU2007265475A patent/AU2007265475B2/en active Active
- 2007-06-26 WO PCT/US2007/014873 patent/WO2008002591A2/en active Application Filing
- 2007-06-26 ES ES07796488T patent/ES2376396T3/es active Active
- 2007-06-26 CA CA2654661A patent/CA2654661C/en active Active
- 2007-06-26 US US11/823,251 patent/US20080096900A1/en not_active Abandoned
-
2011
- 2011-04-14 US US13/087,261 patent/US8426358B2/en active Active
-
2013
- 2013-03-26 US US13/851,019 patent/US20130273024A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20080096900A1 (en) | 2008-04-24 |
EP2037928B1 (de) | 2012-01-11 |
AU2007265475B2 (en) | 2010-08-19 |
EP2037928A2 (de) | 2009-03-25 |
EP2452683A3 (de) | 2012-08-22 |
US20110206652A1 (en) | 2011-08-25 |
ES2376396T3 (es) | 2012-03-13 |
CA2787343C (en) | 2016-08-02 |
AU2007265475A1 (en) | 2008-01-03 |
WO2008002591A2 (en) | 2008-01-03 |
CA2654661C (en) | 2012-10-23 |
EP2452683A2 (de) | 2012-05-16 |
CA2787343A1 (en) | 2008-01-03 |
CA2654661A1 (en) | 2008-01-03 |
US8426358B2 (en) | 2013-04-23 |
US20130273024A1 (en) | 2013-10-17 |
WO2008002591A3 (en) | 2008-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE540681T1 (de) | Verfahren zur behandlung von atherosklerose | |
DE602005011656D1 (de) | Verfahren zur behandlung von dickdarmkrebs mit botulinum neurotoxin | |
ATE489955T1 (de) | Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten | |
DE602006018354D1 (de) | Verfahren zur behandlung von abnormalem zellwachstum | |
DE602007006479D1 (de) | Verfahren und vorrichtungen zur behandlung von mehreren bohrlochintervallen | |
WO2008115469A3 (en) | Role of hedgehog signaling in atherosclerosis and cardiovascular disease | |
DE602005008970D1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten | |
DE602007012133D1 (de) | Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten | |
ATE515261T1 (de) | Zusammensetzungen zur behandlung von diabetes | |
ATE474602T1 (de) | Verfahren zur behandlung von hiv-infektion | |
WO2007120656A3 (en) | Uses and compositions for treatment of rheumatoid arthritis | |
WO2008137236A3 (en) | Treatment of age-related macular degeneration using inhibitors of complement factor d | |
ATE554091T1 (de) | Aminotetrahydropyrane als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes | |
WO2008063213A3 (en) | Uses and compositions for treatment of psoriatic arthritis | |
DE602006015182D1 (de) | Zusammensetzung und verfahren zur kontrolle von insekten | |
DE602005010649D1 (de) | Server, Serversystem und Verfahren zur Zustellung von E-mails | |
DE602006016044D1 (de) | Verfahren und Vorrichtung zur Fehlerverdeckung. | |
DE602007001518D1 (de) | Verfahren zur Behandlung von Beton | |
ATE442211T1 (de) | Verfahren und verwandte anlage zur herstellung von langen stahlprodukten ohne unterbrechung | |
WO2009015314A3 (en) | Modified lecithin-cholesterol acyltransferase enzymes | |
DE602004021847D1 (de) | Verfahren zur prävention und behandlung von diabetes mit neurturin | |
DE112004001806D2 (de) | Verfahren zur Selbstjustierenden Verkleinerung von Strukturen | |
ATE411803T1 (de) | Verfahren zur behandlung von schwerer herzinsuffizienz und medikament dafür | |
DE602005021766D1 (de) | Verfahren zur behandlung von atherosklerose | |
WO2005118946A3 (en) | Self-steaming benefit composition |